Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | PRKDC | P78527 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | LITAF | Q99732 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29153724 | 1.00 | PIK3CA (0.41) | PIK3CAMTORPRKDCPIK3CDTNF | |
| SCHEMBL29153725 | 1.00 | PIK3CA (0.41) | PIK3CAMTORPRKDCPIK3CDTNF | |
| SCHEMBL23476336 | 0.92 | PIK3CA (0.39) | PIK3CAMTORPRKDCPIK3CDPREP | |
| SCHEMBL21593726 | 0.89 | PIK3CA (0.47) | PIK3CAMTORPRKDCPIK3CDTNF | |
| SCHEMBL21593713 | 0.89 | PIK3CA (0.47) | PIK3CAMTORPRKDCPIK3CDTNF | |
| SCHEMBL21593644 | 0.89 | PIK3CA (0.47) | PIK3CAMTORPRKDCPIK3CDTNF | |
| SCHEMBL23452640 | 0.87 | PRKDC (0.38) | PIK3CAMTORPRKDC | |
| SCHEMBL21593686 | 0.85 | PIK3CA (0.52) | PIK3CAMTORPRKDCTNFLITAF | |
| SCHEMBL21593599 | 0.82 | USP1 (0.40) | PIK3CAPIK3CDGPR119PREP | |
| SCHEMBL21593597 | 0.82 | USP1 (0.40) | PIK3CAPIK3CDGPR119PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | PIK3CA 1179/4885MTOR 1844/4885PRKDC 274/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | PIK3CA 1081/4885MTOR 1496/4885PRKDC 337/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | PIK3CA 1179/4885MTOR 1844/4885PRKDC 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.